Antibodies at work in the time of SARS-CoV-2
Even after a decade of continuous emergence of coronaviruses, there aren’t any licenced vaccines or therapeutics against the deadly infection. The age-old passive immunization with protective antibodies to neutralize the virus is one of the strategies for emergency prophylaxis and therapy for COVID-...
- Autores:
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/12857
- Acceso en línea:
- https://doi.org/10.1016/j.jcyt.2020.08.009
http://hdl.handle.net/20.500.12010/12857
- Palabra clave:
- SARS-CoV-2
Immunotherapy
Convalescent plasma therapy
Monoclonal antibodies
Nanobodies
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Acceso restringido